FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561286475> ?p ?o ?g. }

• W2561286475 abstract "Resistance to androgen deprivation therapies is characterized by the persistent activation of the androgen receptor (AR). Traditional approaches for the development of novel androgen deprivation therapies have focused on inhibition of AR activity by blocking the production or binding of androgens to the AR. These novel treatment strategies have shown improvements, however, patients still develop castration-resistant disease. Continued AR activity in castration-resistant prostate cancer (CRPC) may be the result of ligand dependent or ligand independent mechanisms. Antisense oligonucleotides (ASO) have the ability to block specific genes inhibiting the associated proteins thus providing an alternate treatment strategy for CRPC. Here, we investigated the in vivo antitumor effects of a generation 2.5 ASO targeting the mouse AR in a PTEN-deficient mouse model of prostate cancer. Pharmacodynamic analysis demonstrated strong inhibition of target RNA by the AR-ASO in prostate tumor tissues. The AR-ASO also exhibited strong suppression of AR protein levels in prostate tumors as demonstrated by western blot analysis. Immunohistochemical analysis confirmed reduced levels of AR expression and transcriptional activity in tumor tissue. Furthermore, AR was also inhibited in normal tissues of the accessory sex glands. The treatment efficacy of the AR-ASO was evaluated in pharmacological intervention trials in mice with castration-naive prostate cancer (CNPC) and CRPC. Treatments effects in CNPC were also compared to androgen deprivation by surgical castration. Compared to saline treated controls, tumor growth was significantly inhibited by the AR-ASO (34%) and was comparable to that of surgical castration (38%). In the CRPC model, significant suppression of tumor growth (10% vs control) was also observed in mice treated with the AR-ASO. Furthermore, strong inhibition of AR expression and activity was observed in AR-ASO-treated mice harboring either CNPC or CRPC, but not in mice treated with surgical castration. Gene expression profiling using the Fluidigm Biomark platform revealed that 40 AR-dependent target genes were significantly altered in CNPC after treatment with the AR-ASO; 34 of these genes were also significantly changed following castration. A decrease of ERK phosphorylation in was observed in AR-ASO-treated mice in both CNPC and CRPC intervention models and was associated with decreased protein levels of AR. These findings demonstrate that treatment with generation 2.5 AR-ASO is effective against preclinical mouse models of prostate cancer and may provide a promising approach to overcoming treatment resistance of CRPC. Citation Format: Marco A. De Velasco, Yurie Kura, Naomi Ando, Emiko Fukushima, Barry R. Davies, Hayley Campbell, Yuji Hatanaka, Yutaka Yamamoto, Nobutaka Shimizu, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Inhibition of mouse PTEN-deficient prostate cancer with next generation antisense oligonucleotide targeting the androgen receptor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4212. doi:10.1158/1538-7445.AM2015-4212" @default.
• W2561286475 created "2017-01-06" @default.
• W2561286475 creator A5000275517 @default.
• W2561286475 creator A5004282323 @default.
• W2561286475 creator A5016297157 @default.
• W2561286475 creator A5044704087 @default.
• W2561286475 creator A5047104997 @default.
• W2561286475 creator A5047840224 @default.
• W2561286475 creator A5051123041 @default.
• W2561286475 creator A5057857434 @default.
• W2561286475 creator A5058934672 @default.
• W2561286475 creator A5059877323 @default.
• W2561286475 creator A5060375630 @default.
• W2561286475 creator A5061277451 @default.
• W2561286475 creator A5061542577 @default.
• W2561286475 creator A5083740330 @default.
• W2561286475 date "2015-08-01" @default.
• W2561286475 modified "2023-09-26" @default.
• W2561286475 title "Abstract 4212: Inhibition of mouse PTEN-deficient prostate cancer with next generation antisense oligonucleotide targeting the androgen receptor" @default.
• W2561286475 doi "https://doi.org/10.1158/1538-7445.am2015-4212" @default.
• W2561286475 hasPublicationYear "2015" @default.
• W2561286475 type Work @default.
• W2561286475 sameAs 2561286475 @default.
• W2561286475 citedByCount "0" @default.
• W2561286475 crossrefType "proceedings-article" @default.
• W2561286475 hasAuthorship W2561286475A5000275517 @default.
• W2561286475 hasAuthorship W2561286475A5004282323 @default.
• W2561286475 hasAuthorship W2561286475A5016297157 @default.
• W2561286475 hasAuthorship W2561286475A5044704087 @default.
• W2561286475 hasAuthorship W2561286475A5047104997 @default.
• W2561286475 hasAuthorship W2561286475A5047840224 @default.
• W2561286475 hasAuthorship W2561286475A5051123041 @default.
• W2561286475 hasAuthorship W2561286475A5057857434 @default.
• W2561286475 hasAuthorship W2561286475A5058934672 @default.
• W2561286475 hasAuthorship W2561286475A5059877323 @default.
• W2561286475 hasAuthorship W2561286475A5060375630 @default.
• W2561286475 hasAuthorship W2561286475A5061277451 @default.
• W2561286475 hasAuthorship W2561286475A5061542577 @default.
• W2561286475 hasAuthorship W2561286475A5083740330 @default.
• W2561286475 hasConcept C121608353 @default.
• W2561286475 hasConcept C126322002 @default.
• W2561286475 hasConcept C190283241 @default.
• W2561286475 hasConcept C2776235491 @default.
• W2561286475 hasConcept C2777609662 @default.
• W2561286475 hasConcept C2777899217 @default.
• W2561286475 hasConcept C2777911890 @default.
• W2561286475 hasConcept C2780192828 @default.
• W2561286475 hasConcept C2910322876 @default.
• W2561286475 hasConcept C502942594 @default.
• W2561286475 hasConcept C55493867 @default.
• W2561286475 hasConcept C61367390 @default.
• W2561286475 hasConcept C71315377 @default.
• W2561286475 hasConcept C71924100 @default.
• W2561286475 hasConcept C86554907 @default.
• W2561286475 hasConcept C86803240 @default.
• W2561286475 hasConceptScore W2561286475C121608353 @default.
• W2561286475 hasConceptScore W2561286475C126322002 @default.
• W2561286475 hasConceptScore W2561286475C190283241 @default.
• W2561286475 hasConceptScore W2561286475C2776235491 @default.
• W2561286475 hasConceptScore W2561286475C2777609662 @default.
• W2561286475 hasConceptScore W2561286475C2777899217 @default.
• W2561286475 hasConceptScore W2561286475C2777911890 @default.
• W2561286475 hasConceptScore W2561286475C2780192828 @default.
• W2561286475 hasConceptScore W2561286475C2910322876 @default.
• W2561286475 hasConceptScore W2561286475C502942594 @default.
• W2561286475 hasConceptScore W2561286475C55493867 @default.
• W2561286475 hasConceptScore W2561286475C61367390 @default.
• W2561286475 hasConceptScore W2561286475C71315377 @default.
• W2561286475 hasConceptScore W2561286475C71924100 @default.
• W2561286475 hasConceptScore W2561286475C86554907 @default.
• W2561286475 hasConceptScore W2561286475C86803240 @default.
• W2561286475 hasLocation W25612864751 @default.
• W2561286475 hasOpenAccess W2561286475 @default.
• W2561286475 hasPrimaryLocation W25612864751 @default.
• W2561286475 hasRelatedWork W1655166217 @default.
• W2561286475 hasRelatedWork W1882606371 @default.
• W2561286475 hasRelatedWork W1996993772 @default.
• W2561286475 hasRelatedWork W2011714693 @default.
• W2561286475 hasRelatedWork W2046163257 @default.
• W2561286475 hasRelatedWork W2067667653 @default.
• W2561286475 hasRelatedWork W2095303664 @default.
• W2561286475 hasRelatedWork W2105592988 @default.
• W2561286475 hasRelatedWork W2115057288 @default.
• W2561286475 hasRelatedWork W2139711232 @default.
• W2561286475 hasRelatedWork W2317595377 @default.
• W2561286475 hasRelatedWork W2483792840 @default.
• W2561286475 hasRelatedWork W2512774654 @default.
• W2561286475 hasRelatedWork W2740652713 @default.
• W2561286475 hasRelatedWork W2883445005 @default.
• W2561286475 hasRelatedWork W2887517163 @default.
• W2561286475 hasRelatedWork W2887844094 @default.
• W2561286475 hasRelatedWork W2897146989 @default.
• W2561286475 hasRelatedWork W3197255165 @default.
• W2561286475 hasRelatedWork W3205420313 @default.
• W2561286475 isParatext "false" @default.
• W2561286475 isRetracted "false" @default.
• W2561286475 magId "2561286475" @default.
• W2561286475 workType "article" @default.